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Introduction: The presence of ground glass opacity (GGO) on high-
resolution computed tomography (HRCT) is well known to be pathologi-
cally closely associated with adenocarcinoma in situ. Recently, measuring 
the tumor diameter including areas of GGO on HRCT has been reported 
to possibly overestimate the T status. The purpose of this study was to 
evaluate the significance of the tumor size measured eliminating the area 
of GGO on HRCT as a prognostic factor and to propose a refined TNM 
classification based on modified T descriptors.
Methods: Four hundred seventy-five patients with clinical T1a-
T2bN0M0 non-small-cell lung cancer underwent surgical resec-
tion. All tumors were reclassified based on the diameter measured 
eliminating the GGO area on HRCT according to the seventh TNM 
classification of lung cancer. We defined this new classification as 
modified T descriptors categorizing into five groups: mTis, mT1a, 
mT1b, mT2a, and mT2b. The overall survival rates of the patients in 
the current and modified staging groups were evaluated.
Results: The 5-year survival rates were 88% and 82% in the patients 
with T1a and T1b tumors and 90% and 75% in the patients with 
mT1a and mT1b tumors, respectively. The differences in the survival 
rate of the patients classified by using mT1a and the other modified T 
descriptors were more clearly separated statistically than those of the 
patients classified by using the current T1a and other T descriptors.
Conclusion: The modified T descriptors of the tumor size measured 
eliminating the GGO component on HRCT more clearly classified 
the prognoses of patients with early lung cancer than did the current 
T classification.
Key Words: Tumor, node, metastasis classification, Lung cancer, 
Staging, Tumor size, Ground glass opacity.
(J Thorac Oncol. 2013;8: 1551–1557)
Since the introduction of low-dose helical computed tomog-raphy (CT) in lung cancer screening, small primary lung 
cancers that could not previously be detected with conven-
tional radiography have become identifiable at earlier and 
potentially more curable stages.1,2 Among the small nodules 
detected during CT screening, many cases of adenocarcinoma 
have been found.1,3 The prevalence of adenocarcinoma, espe-
cially that of adenocarcinoma with a lepidic growth pattern, 
has markedly increased in recent years as the most frequent 
histologic subtype of lung cancer.4–6
Some cases of adenocarcinoma exhibit areas of ground 
glass opacity (GGO) on high-resolution CT (HRCT) which 
reflect a lepidic growth pattern of tumor cells microscopi-
cally.7 Therefore, lung tumors that display areas of focal GGO 
on HRCT contain components of pathologic lepidic tumor 
growth.8 The majority of areas of pure GGO on HRCT have 
been shown to be adenocarcinoma in situ lesions pathologi-
cally.9,10 Lung adenocarcinomas exhibiting part-solid nodules 
with a large proportion of GGO have also been demonstrated 
to tend to be less invasive than solid or mostly solid tumors of 
the same size.7,8,11,12 These findings are reflected in the recently 
revised international multidisciplinary classification of lung 
adenocarcinoma sponsored by the International Association 
for the Study of Lung Cancer, American Thoracic Society 
and European Respiratory Society.13 In these new criteria, the 
radiologic features are described as part of a multidisciplinary 
approach to the comprehensive classification of adenocarci-
noma. With respect to early adenocarcinoma in particular, a 
crucial question has been raised: How should the tumor size 
be measured?
Since mid-1970s, the tumor size has been a primary 
descriptive and significant prognostic factor for lung cancer in 
the tumor, node, metastasis (TNM) classification of the Union 
for International Cancer Control (UICC) staging system.14 
According to the present classification15 revised in 2009, the 
T classification of T1a to T3 was changed as follows: tumors 
with diameter of 2 cm or less are classified as T1a, tumors with 
diameter of greater than 2 cm but not more than 3 cm are clas-
sified as T1b, tumors with diameter of greater than 3 cm but 
more than 5 cm are classified as T2a, tumors with diameter of 
greater than 5 cm but not more than 7 cm are classified as T2b, 
Copyright © 2013 by the International Association for the Study of Lung 
Cancer
ISSN: 1556-0864/13/0812-1551
Prognostic Impact of Tumor Size Eliminating the Ground 
Glass Opacity Component
Modified Clinical T Descriptors of the Tumor, Node, Metastasis 
Classification of Lung Cancer
Shota Nakamura, MD,* Takayuki Fukui, MD,* Tetsuo Taniguchi, MD,* Noriyasu Usami, MD,*  
Koji Kawaguchi, MD,* Futoshi Ishiguro, MD,* Akihiro Hirakawa, PhD,† and Kohei Yokoi, MD*
*Department of Thoracic Surgery, Nagoya University Graduate School 
of Medicine, Nagoya, Japan; and †Center for Advanced Medicine and 
Clinical Research, Nagoya University Graduate School of Medicine, 
Nagoya, Japan.
Disclosure: The authors declare no conflict of interest.
Address for correspondence: Shota Nakamura, MD, Department of Thoracic 
Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-
cho, Showa-ku, Nagoya 466–8550, Japan. E-mail: shota197065@med.
nagoya-u.ac.jp
ORIGINAL ARTICLE
1552 Copyright © 2013 by the International Association for the Study of Lung Cancer
Nakamura et al. Journal of Thoracic Oncology ®  •  Volume 8, Number 12, December 2013
and tumors with diameter of greater than 7 cm are classified as 
T3. Recently, suggestions for the next revisions of the UICC 
and American Joint Committee on Cancer staging systems 
have been proposed. Tsutani et al.,16 Matsuguma et al.,17 and 
Maeyashiki et al.18 demonstrated that the solid-area diameter 
without GGO on HRCT is a more effective measurement of 
tumor nodules for predicting the prognoses of patients with 
non–small-cell lung cancer and proposed the measurement of 
the solid-area diameter as the T descriptor in the future revi-
sion of the TNM classification.
The purpose of this study was to evaluate the signifi-
cance of the tumor size measured eliminating the area of GGO 
as a prognostic factor based on modified T descriptors.
PATIENTS AND METHODS
This study was approved by the institutional review 
board of Nagoya University Hospital, Nagoya, Japan. Between 
January 2005 and December 2010, 700 patients with primary 
lung cancer underwent surgical resection with curative intent 
at our institution. Of these patients, 490 were given a clini-
cal diagnosis of T1aN0M0 to T2bN0M0 non–small-cell car-
cinoma. Among them, 475 underwent HRCT and provided 
follow-up data; these patients constituted the study popula-
tion. All patients underwent physical examination, chest radi-
ography, and magnetic resonance imaging of the brain and CT 
of the chest and abdomen for tumor staging and an evaluation 
of resectability before surgery. The patients were scheduled 
for checkups every 1 to 3 months for 2 years after surgery and 
every 6 months thereafter. In patients with a high risk of recur-
rence, chest CT was performed every 6 to 12 months by phy-
sician’s recommendation. Furthermore, when the occurrence 
of recurrence was suspected, additional imaging surveys were 
performed.
HRCT images were obtained with use of 4- or 16-row 
multislice CT scanners (Aquilion; Toshiba Medical Systems, 
Tokyo, Japan) without contrast medium. An image sliced 
transversely at the center of the nodule was selected to mea-
sure the tumor diameter. For image reconstruction, we used a 
0.5- to 2.0-mm slice thickness and a lung algorithm (FC50, 
FC82, FC83). The image size was 512 × 512 pixels. Image 
data stored in the Digital Imaging and Communications in 
Medicine format were transferred from the CT scanner to a 
personal computer for the image analysis. The images were 
displayed at lung window settings of a level of −600 HU and 
a width of 1,500 HU. Two authors (SN and TF) manually 
measured the maximum diameter of the pulmonary nodules 
on a computer screen and distinguished areas of GGO from 
solid regions, removing air space, air bronchograms, and large 
vessels.
GGO was defined as the presence of a hazy increased 
opacity of the lung with preservation of the bronchial and 
vascular margins. The solid area of the tumor was defined as 
the area observed after eliminating all regions of GGO in the 
entire nodule. We defined the size of the solid component as 
the maximum dimension of the solid component after exclud-
ing the areas of GGO at the lung windows (Fig. 1). The tumor 
size calculated eliminating the GGO component was primar-
ily measured on axial slices, and when the maximum size was 
obtained on a coronal or sagittal slice of HRCT, the largest 
size on the slice was selected. Discrepancies in evaluating the 
diameter of the solid component were resolved by averag-
ing. All tumors were reclassified on the basis of the diameter 
FIGURE 1.  Examples of whole tumor 
sizes and tumor sizes calculated eliminat-
ing the areas of GGO (solid tumor size) on 
high-resolution computed tomography. A, 
Whole tumor size: 2.8 cm (T1b) and solid 
tumor size: 2.5 cm (mT1b). B, Whole and 
solid tumor sizes: 2.1 cm (T1b) and 0.7 cm 
(mT1a). C, Whole and solid tumor sizes: 
1.2 cm (T1a) and 1.2 cm (mT1a). D, Whole 
and solid tumor sizes: 2.1 cm (T1b) and 
0.0 cm (mTis). GGO, ground glass opacity.
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measured eliminating the area of GGO according to the sev-
enth TNM classification of lung cancer, and this new classi-
fication was defined as modified T descriptors categorizing 
into five groups: mTis, mT1a, mT1b, mT2a, and mT2b. The 
rates of overall survival (OS) and disease-free survival (DFS) 
were evaluated according to the current and modified staging 
groups.
The concordance of the categorizations of the current 
and modified T descriptors was examined using the weighted 
κ coefficient. OS was defined as the time from surgery to death 
from any cause or to the date of the last visit of patients with-
out events. DFS was defined as the time from surgery to the 
detection of relapse and metastasis, to death from any cause, 
or to the date of the last visit of patients without events. OS 
and DFS curves were estimated by using the Kaplan–Meier 
method and compared by using the log-rank test. Univariate 
and multivariate Cox regression analyses were used to esti-
mate the hazard ratios, 95% confidence intervals, and effects 
of the clinical variables on the survival rates. The separation 
index proposed by Sauerbrei et al.19 was used to evaluate the 
degree of separation of the survival curves among the four 
groups determined on the basis of the two T classifications. A 
larger separation index indicates a better degree of separation. 
A two-sided p value of less than 0.05 was considered to be sta-
tistically significant. All statistical analyses were performed 
by using the SAS software package (version 9.3; SAS Institute 
Inc., Cary, NC).
RESULTS
The characteristics of the 475 patients are summarized 
in Table 1. According to the current TNM staging system, the 
tumors were distributed as follows: T1a, n = 191 (40.2%); 
T1b, n = 147 (30.9%); T2a, n = 124 (26.2%); and T2b, 
n = 13 (2.7%). When applying the modified T classification, 
the tumors were distributed as follows: mTis, n = 16 (3.4%); 
mT1a, n = 253 (53.3%); mT1b, n = 112 (23.6%); mT2a, 
n = 81 (17.1%); and mT2b, n = 13 (2.7%). Comparing the 
two distributions classified according to each T descriptor, 
the proportion of tumors in the mT1a class was remarkably 
increased after the reclassification of T1b and T2a diseases. 
Sixteen tumors were shifted to the mTis status from the T1a, 
T1b, and T2a status, and 62 tumors were shifted to the mT1a 
status from the T1b and T2a status, with most tumors chang-
ing from T1b to mT1a (n = 50) (Fig. 2). The weighted κ coeffi-
cient of the concordance of categorization between the current 
and modified T classifications was 0.73.
The OS curves and 5-year survival rates according 
to the current and modified T staging systems are shown in 
Figure 3. Table 2 shows the results of the univariate and mul-
tivariate Cox regression analyses of OS based on the current 
and modified T classifications. Other prognostic factors in the 
analyses included age, sex, and histological type. The differ-
ence in the survival functions between mT1a and mT1b was 
statistically significant (p = 0.0042 and p = 0.0446 for the 
univariate and multivariate analyses, respectively), whereas 
no significant differences were observed between T1a and 
T1b (p = 0.1524 and p = 0.2158 for the univariate and multi-
variate analyses, respectively). The differences in the survival 
functions between mT1a and all other modified T descriptors 
except mTis were significant, as were the differences between 
T1a and the other T descriptors except for T1b. The separation 
indices of the OS curves for the current and modified T clas-
sifications were 4.75 and 5.31, respectively.
The DFS curves and 5-year DFS rates according to 
the current and modified T classification systems are shown 
in Figure 4. Table 3 shows the results of the univariate and 
TABLE 1.  Patient Demographics
Total patients 475
Observation period (month)
  Median 40
  Range 2–101
Age (yr)
  Median 69
  Range 26–87
Sex
  Men 304 (64.0%)
  Women 171 (36.0%)
Maximum tumor diameter including GGO area (mm)
  Median 26
  Range 7–70
Maximum tumor diameter eliminated GGO area (mm)
  Median 25
  Range 0–70
Clinical stage according to the current TNM classification
  T1a N0 M0 191 (40.2%)
  T1b N0 M0 147 (30.9%)
  T2a N0 M0 124 (26.2%)
  T2b N0 M0 13 (2.7%)
Histology
  Adenocarcinoma 353
  Squamous cell carcinoma 77
  Others 45
GGO, ground glass opacity; TNM, tumor, node, metastasis.
FIGURE 2.  Distribution of the patients according to the cur-
rent and modified T status groups. The proportion of patients 
with mT1a disease increased remarkably because these 
tumors were reclassified from T1b and T2a.
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multivariate Cox regression analyses of DFS based on the 
current and modified T classifications. The difference in the 
survival functions between mT1a and mT1b was statistically 
significant (p = 0.0007 and p = 0.0033 for the univariate and 
multivariate analyses, respectively), whereas no significant 
differences were observed between T1a and T1b (p = 0.1840 
and p = 0.2344 for the univariate and multivariate analyses, 
respectively). Similar to the results for OS, according to 
the univariate and multivariate Cox regression analyses, the 
differences in the survival functions between mT1a and all 
other modified T descriptors except mTis were significant, as 
were the differences between T1a and the other T descriptors 
except for T1b. The separation indices of the DFS curves for 
the current and modified T classifications were 4.77 and 6.69, 
respectively.
The correlations between the current and modified 
T statuses and pathological findings are shown in Table 4. 
Among the tumors downstaged by modifying the T status, all 
except one case of squamous cell carcinoma were adenocar-
cinomas. The squamous cell carcinoma lesion presented as a 
peripheral part-solid nodule of the right lower lobe of the lung 
on HRCT. The GGO area was pathologically revealed to be 
obstructive pneumonia in contact with the solid part of the 
tumor. All tumors classified as having an mTis status present-
ing as pure GGO nodules on HRCT were revealed to be early 
adenocarcinomas pathologically, and all patients with mTis 
TABLE 2.  Results of the Univariate and Multivariate Cox Regression Analyses of Overall Survival According to the Current and 
Modified T Classifications
Clinical Staging Number
Univariate Multivariate
HR 95% CI p HRa 95% CI p
Current
  T1a 191 1 1
  T1b 147 1.52 (0.85–2.79) 0.1524 1.46 (0.80–2.66) 0.2158
  T2a 124 2.22 (1.26–3.93) 0.0061 1.90 (1.07–3.38) 0.0295
  T2b 13 10.68 (4.44–25.71) <0.0001 7.62 (3.11–18.67) <0.0001
Modified
  mTis 16 0.63 (0.09–4.64) 0.6491 0.76 (0.10–5.66) 0.7912
  mT1a 253 1 1
  mT1b 112 2.29 (1.30–4.03) 0.0042 1.81 (1.01–3.23) 0.0446
  mT2a 81 3.14 (1.79–5.50) <0.0001 2.65 (1.47–4.79) 0.0012
  mT2b 13 11.76 (4.99–27.73) <0.0001 8.50 (3.53–20.46) <0.0001
Multivariate analysis: HR adjusted by age, sex, and histological types.
HR, hazard ratio; CI, confidence interval.
FIGURE 3.  Overall survival based on the current T classification (A) and modified T classification (B). NE, not evaluable.
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tumors survived without recurrence, except for one who died 
of other disease.
DISCUSSION
The TNM classification of cancers proposed by the 
UICC is a widely accepted guide for estimating prognosis, 
selecting therapy, and facilitating the development of new 
treatment strategies. In 1974, the American Joint Committee 
on Cancer and UICC applied the TNM cancer staging sys-
tem to lung cancer.20 In the current edition issued in 2009, 
the International Association for the Study of Lung Cancer 
Staging Committee changed the size classification of T1a to 
T3.15 According to the TNM classification, the T descriptor 
defines the primary tumor based on the size, airway location, 
and degree of local invasion. The tumor size is one of the 
most important prognostic determinants in this classification 
and can be determined before surgery by using radiological 
imaging.
Recent improvements in imaging technology and the 
widespread use of CT scans for screening have increased the 
probability of detecting small-sized lung cancers. Small-sized 
lung cancers often contain nonsolid components exhibiting 
areas of GGO with various proportions of solid components 
on HRCT. Many investigators have reported that the presence 
of GGO on HRCT is closely associated with a lepidic growth 
pattern in patients with adenocarcinoma of the lungs.21–23 
FIGURE 4.  Disease-free survival based on the current T classification (A) and modified T classification (B). NE, not evaluable
TABLE 3.  Results of the Univariate and Multivariate Cox Regression Analyses of Disease-Free Survival According to the Current 
and Modified T Classifications
Clinical Staging Number
Univariate Multivariate
HR 95% CI p HR 95% CI p
Current
  T1a 191 1 1
  T1b 147 1.41 (0.85–2.34) 0.1840 1.36 (0.82–2.27) 0.2158
  T2a 124 2.41 (1.50–3.85) 0.0003 2.16 (1.34–3.48) 0.0016
  T2b 13 7.97 (3.61–17.59) <0.0001 6.46 (2.89–14.46) <0.0001
Modified
  mTis 16 0.45 (0.06–3.31) 0.4341 0.48 (0.07–3.51) 0.4682
  mT1a 253 1 1
  mT1b 112 2.32 (1.43–3.78) 0.0007 2.10 (1.28–3.46) 0.0033
  mT2a 81 3.89 (2.44–6.20) <0.0001 3.72 (2.28–6.06) <0.0001
  mT2b 13 9.33 (4.27–20.38) <0.0001 8.11 (3.66–17.98) <0.0001
Multivariate analysis: HR adjusted by age, sex, and histological types
HR, hazard ratio; CI, confidence interval.
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Furthermore, a large prospective study on clinical stage IA 
cancer of the lungs led to a definition of radiological noninva-
sive adenocarcinoma of the lungs based on the findings of CT 
scans.24,25 Those data demonstrated that patients with radiolog-
ical noninvasive adenocarcinoma of the lungs have very good 
prognoses, with tumors that are found to exhibit a minimally 
invasive nature on pathological examinations. On the basis 
of the results of these studies, measuring the tumor diameter, 
including the area of GGO, on HRCT has been reported to 
possibly overestimate the T status.8,9,26 The findings of these 
reports are reflected in the recently revised international mul-
tidisciplinary classification of lung adenocarcinoma.13 With 
respect to the radiologic features of early adenocarcinoma, a 
crucial question has been raised: How should the tumor size 
be measured?
Many investigators have reported methods for assessing 
part-solid tumors. Nevertheless, a few reports have investi-
gated the relevance of the tumor appearance for the progno-
sis or possibility of recurrence. Tsutani et al.16 evaluated the 
role of the solid tumor size in cases of clinical stage IA lung 
adenocarcinoma and retrospectively compared the prognostic 
significance of the solid tumor size with that of the size of the 
entire tumor. They found that the solid tumor size more clearly 
reflects the pathologic findings related to tumor aggressive-
ness and/or prognosis. Subsequently, Matsuguma et al.17 
compared the solid area and whole nodule diameters with the 
proportion of GGO in tumors with respect to estimating tumor 
invasiveness and recurrence and demonstrated that evaluating 
the combination of the solid-area diameter and the proportion 
of GGO was the best method. Nevertheless, they also reported 
that adding the proportion of GGO for assessing tumors is 
complicated with regard to the staging system and difficult to 
perform in daily practice. Consequently, they concluded that 
the solid-area diameter is more suitable for predicting less 
invasive lung cancer and/or postoperative recurrence than the 
whole tumor diameter. These results supported and encour-
aged our present study, which assessed the value of this mea-
surement method as a prognostic factor.
Concerning the image settings of HRCT for assessing 
lung nodules, many other studies, including above mentioned 
two studies and our study, used almost the same lung window 
settings and arrived at similar results.10,18,24,27–29 We believe that 
lung window settings used in daily practice are the most useful 
and reasonable settings.
The general rules of the TNM system state in the TNM 
supplement30 that when size is a criterion for the T category, 
it is a measurement of the invasive component, which means 
that measurements of the tumor diameter should eliminate the 
area of GGO on HRCT. This description also prompted us to 
examine the significance of measuring the tumor size elimi-
nating the area of GGO, in other words, measuring the tumor 
size including only the invasive area on HRCT.
In our series, the OS curves of the patients classified 
with our modified T descriptors were more clearly separated 
than those of the patients classified with the current T descrip-
tors included in the seventh edition of the TNM classification. 
Similarly, the DFS curves of the patients classified with the 
modified T descriptors were more clearly separated in each 
curve than those of the patients classified by using the cur-
rent system. The modified T classification divided the survival 
curves more clearly than the current T classification because 
the component of a lepidic growth pattern (the noninvasive 
component) was eliminated from the whole tumor diameter 
radiologically by eliminating the area of GGO on HRCT. In 
other words, the eliminated area of GGO may not influence 
the patient’s survival.
Nevertheless, the T status of all but one nonadenocar-
cinoma case was not affected by the use of our modified T 
descriptors. This is because almost all nonadenocarcinoma 
nodules presented as pure-solid lesions on HRCT. Moreover, 
the survival of these patients was compatible with that of the 
adenocarcinoma patients according to the modified T descrip-
tors. On the basis of these results, we considered that the 
method which measures the tumor size by eliminating the 
GGO component can be adapted for both adenocarcinoma 
and other non–small-cell lung cancers. Matsuguma et al.17 
reported the effectiveness of measuring only the solid diam-
eter of the tumor for predicting less invasive lung cancer and 
the occurrence of postoperative recurrence in patients with 
non–small-cell lung cancer.
To examine the ability to predict the prognosis based 
on the modified T classification, we compared the separation 
index, a measure of the degree of separation of the survival 
curves among the four groups, between the modified and cur-
rent T classifications. The index was calculated by using the 
hazard ratios determined after adjusting for age, sex, and his-
tological type, as shown in Tables 3 and 4. A larger value indi-
cates a better degree of separation. The adjusted hazard ratios 
for OS and DFS and their separation indices demonstrated 
that our modified classification more effectively predicted the 
prognosis than the current classification.
Our study had several limitations. First, our study was of 
retrospective design. Nevertheless, in this study, we analyzed 
patient survival by using two methods of measuring the tumor 
diameter based only on preoperative characteristics, regard-
less of the postsurgical results. Second, we did not investigate 
TABLE 4.  Comparison between the Current and Modified T 
Statuses and Pathological Findings
Clinical Staging
Adenocarcinoma
OthersAIS* MIA* IA* SQ
Current
  T1a 16 23 107 26 19
  T1b 6 16 90 25 10
  T2a 0 12 75 22 15
  T2b 0 0 8 4 1
Modified
  mTis 12 4 0 0 0
  mT1a 10 43 154 27 19
  mT1b 0 4 74 24 10
  mT2a 0 0 44 22 15
  mT2b 0 0 8 4 1
AIS, adenocarcinoma in situ; MIA, minimally invasive adenocarcinoma; IA, 
invasive adenocarcinoma; SQ, squamous cell carcinoma.
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the relationship between the T descriptors and positron emis-
sion tomography/CT findings in our cohort. Although the 
maximum standardized uptake value on positron emission 
tomography/CT is still not integrated into the TNM classifica-
tion, it may provide additional information preoperatively.31
In conclusion, we reclassified tumors according to the 
size eliminating the area of GGO on HRCT and confirmed 
the OS and DFS rates in patients with clinical T1aN0M0 to 
T2bN0M0 non–small-cell lung cancer. Our present results 
showed that the modified T descriptors eliminating the area 
of GGO on HRCT more clearly classify the prognoses of 
patients with clinically early lung cancer than the current T 
classification did. We believe that our modified T descriptors 
are powerful prognostic factors and indicators for identifying 
the prognosis more clearly. Further investigations are needed 
to assess and compare this method with other measuring 
methods and window settings on HRCT of lung nodules with 
respect to accurately reflecting patient survival.
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